Altogen Biosystems - A Quality Provider of Transfection Reagents and Services
Altogen Biosystems is one of the leading members of the biotechnology market, with over 100 different transfection reagents and services offered. With a focus on genetic applications, Altogen Biosystems has optimized and developed a variety of novel formulations that are specific to certain cell types. Transfection experiments with Altogen transfection reagents are guaranteed to exhibit efficiency, as in house testing of reagents is optimized based on the specific cell line that the transfection reagent is intended for.
Altogen Biosystems provides laboratory contract research services along with transfection reagents; several services include the development of siRNA libraries, ELISA testing, and the generation of stably-transfected cell lines in just 28 days. These xenograft models are essential for testing novel therapeutic drugs involving RNAi technology and gene silencing techniques. Altogen Biosystems has a fleet of staff dedicated to ensuring the quality of experimentation that is suitable to a customer's wishes. Scientists can help pharmaceutical companies bring IND's to FDA approval, and can also conduct the necessary pre-clinical trials in their state-of-the-art laboratory.
The company was started with a focus on engineering novel solutions to transfection without using viral techniques - transferring foreign materials into cells chemically, rather than with a virus that could result in adverse effects. With time the company developed a fleet of stably-transfected cell line xenograft model and optimized the array of transfection reagents to ensure proper functionality.
Recently, Altogen Biosystems has redesigned the AltoFect transfection reagent, designed to work in difficult-to-transfect cells such as primary cells, and has achieved 85% efficiency in vitro. The reagent has opened the path to realistic testing of cells in vitro such that transfection results in the same results as there would be in vivo. Such valuable information is important for considerations relating to pre-clinical testing and further development of a given therapeutic technique. In context of pharmaceuticals, reliable transfection of lymphocytes and primary cells can hold the key to developing gene therapies targeting cancer and other genetically-linked diseases. For a limited time free sample, visit the Altogen Biosystems website.
Altogen Biosystems provides laboratory contract research services along with transfection reagents; several services include the development of siRNA libraries, ELISA testing, and the generation of stably-transfected cell lines in just 28 days. These xenograft models are essential for testing novel therapeutic drugs involving RNAi technology and gene silencing techniques. Altogen Biosystems has a fleet of staff dedicated to ensuring the quality of experimentation that is suitable to a customer's wishes. Scientists can help pharmaceutical companies bring IND's to FDA approval, and can also conduct the necessary pre-clinical trials in their state-of-the-art laboratory.
The company was started with a focus on engineering novel solutions to transfection without using viral techniques - transferring foreign materials into cells chemically, rather than with a virus that could result in adverse effects. With time the company developed a fleet of stably-transfected cell line xenograft model and optimized the array of transfection reagents to ensure proper functionality.
Recently, Altogen Biosystems has redesigned the AltoFect transfection reagent, designed to work in difficult-to-transfect cells such as primary cells, and has achieved 85% efficiency in vitro. The reagent has opened the path to realistic testing of cells in vitro such that transfection results in the same results as there would be in vivo. Such valuable information is important for considerations relating to pre-clinical testing and further development of a given therapeutic technique. In context of pharmaceuticals, reliable transfection of lymphocytes and primary cells can hold the key to developing gene therapies targeting cancer and other genetically-linked diseases. For a limited time free sample, visit the Altogen Biosystems website.
posted by Altogen Labs at 3:17 PM
0 comments
